Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 7/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | IDH2 | P48735 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31127173 | 1.00 | KCNH2 (0.37) | KCNH2IDH1JAK3PTGS2LMNA | |
| SCHEMBL21144171 | 0.88 | KCNH2 (0.40) | KCNH2IDH1PTGS2LMNASMN1; SMN2 | |
| SCHEMBL21144129 | 0.84 | LMNA (0.50) | KCNH2IDH1PTGS2LMNASMN1; SMN2 | |
| SCHEMBL31127073 | 0.82 | GPR119 (0.36) | KCNH2IDH1LMNASMN1; SMN2BRD4 | |
| SCHEMBL21144088 | 0.82 | GPR119 (0.36) | KCNH2IDH1LMNASMN1; SMN2BRD4 | |
| SCHEMBL31127190 | 0.80 | KCNH2 (0.33) | KCNH2IDH1JAK3PTGS2LMNA | |
| SCHEMBL21166208 | 0.80 | KCNH2 (0.33) | KCNH2IDH1JAK3PTGS2LMNA | |
| SCHEMBL19687261 | 0.79 | FFAR2 (0.35) | KCNH2IDH1LMNASMN1; SMN2BRD4 | |
| SCHEMBL21144186 | 0.79 | IDH1 (0.42) | IDH1IDH2GPR119 | |
| SCHEMBL21144114 | 0.78 | GPR119 (0.47) | IDH1IDH2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | KCNH2 22/4885IDH1 3017/4885JAK3 3921/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | KCNH2 22/4885IDH1 3017/4885JAK3 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.